19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 1 of 24 Main Document Pg United States Bankruptcy Court for the: SOUTHERN DISTRICT OF NEW YORK Case number ~rfk~ow~~ Chapter 11 ❑ Check if this an amended filing Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy 4/19 If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and case number (if known). For more information, a separate document, Instructions for Bankruptcy Forms for Non-Individuals, is available. 1. Debtor's name 2. All other names debtor used in the last 8 years Purdue Pharma L.P. I nclude any assumed names, trade names and doing business as names 3. 4. Debtor's federal Employer Identification N umber (EIN) 06-1307484 Debtor's address Principal place of business Mailing address, if different from principal place of business One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901 Number, Street, City, State &ZIP Code P.O. Box, Number, Street, City, State &ZIP Code Fairfield County Location of principal assets, if different from principal place of business Number, Street, City, State &ZIP Code 5. Debtor's website(URL) www.purduepharma.com 6. Type of debtor ❑ Corporation (including Limited Liability Company (LLC)and Limited Liability Partnership (LLP)) ■ Partnership (excluding LLP) ❑ Other. Specify: Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 1 19-23649 Debtor 7. Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 2 of 24 Pg Case number (il known) Purdue Phartna L.P. Describe debtor's business Main Document A. Check one: ❑ Health Care Business(as defined in 11 U.S.C. § 101(27A)) ❑ Single Asset Reai Estate(as defined in 11 U.S.C. § 101(51 B)) ❑ Railroad (as defined in 11 U.S.C. § 101(44)) ❑ Stockbroker(as defined in 11 U.S.C. § 101(53A)) ❑ Commodity Broker(as defined in 11 U.S.C. § 101(6)) ❑ Clearing Bank (as defined in 11 U.S.C. § 781(3)) ■ None of the above B. Check all that apply ❑ Tax-exempt entity(as described in 26 U.S.C. §501) ❑ Investment company, including hedge fund or pooled investment vehicle (as defined in 15 U.S.C. §80a-3) ❑ Investment advisor(as defined in 15 U.S.C. §80b-2(a)(11)) C. NAICS (North American Industry Classification System)4-digit code that best describes debtor. See http://www.uscourts.pov/four-digit-national-association-naics-codes. 3254 8. Under which chapter of the Bankruptcy Code is the debtor £ling? Check one: ~ Chapter 7 ❑ Chapter 9 ■ Chapter 11. Check all that apply' D Debtor's aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than $2,725,625(amount subject to adjustment on 4/01/22 and every 3 years after that). D The debtor is a small business debtor as defined in 11 U.S.C. § 101(51 D). If the debtor is a small business debtor, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return or if all of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(6). ❑ A plan is being filed with this petition. ❑ Acceptances of the plan were solicited prepetition from one or more classes of creditors, in accordance with 11 U.S.C.§ 1126(b). ❑ The debtor is required to file periodic reports (for example, 10K and 10Q) with the Securities and Exchange Commission according to § 13 or 15(d) of the Securities Exchange Act of 1934. File the attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11 (Official Form 201A) with this form. ❑ The debtor is a shell company as defined in the Securities Exchange Act of 1934 Rule 12b-2. ❑ Chapter 12 9. Were prior bankruptcy cases filed by or against the debtor within the last 8 years? ■ No. ❑Yes. If more than 2 cases, attach a separate list. 10. Are any bankruptcy cases pending or being filed by a business partner or an affiliate of the debtor? List all cases. If more than 1, attach a separate list Official Form 201 District When Case number District When Case number ❑ No ■Yes. Debtor See Attached Schedule 1 Relationship District Southern District of New York Case number, if known When Voluntary Petition for Non-Individuals Filing for Bankruptcy Affiliate page 2 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 3 of 24 12. Does the debtor own or have possession of any real property or personal property that needs immediate attention? Pg Case number (if known) Purdue Pharma L.P. 11. Why is the case filed in this disfrict? Main Document Check all that apply: ❑ Debtor has had its domicile, principal place of business, or principal assets in this district for 180 days immediately preceding the date of this petition or for a longer part of such 180 days than in any other district. ■ A bankruptcy case concerning debtor's affiliate, general partner, or partnership is pending in this district. ~ Na ❑Yes. Answer below for each property that needs immediate attention. Attach additional sheets if needed. Why does the property need immediate attention?(Check all that apply.) ❑ It poses or is alleged to pose a threat of imminent and identifiable hazard to public health or safety. What is the hazard? ❑ It needs to be physically secured or protected from the weather. ❑ It includes perishable goods or assets that could quickly deteriorate or lose value without attention (for example, livestock, seasonal goods, meat, dairy, produce, or securities-related assets or other options). ❑ Other Where is the property? Number, Street, City, State &ZIP Code Is the property insured? ❑ No ❑ Yes. Insurance agency Contact name Phone _ Statistical and administrative information 73. Debtor's estimation of available funds Check one: ■ Funds will be available for distribution to unsecured creditors. ❑ After any administrative expenses are paid, no funds will be available to unsecured creditors. 14. Estimated number of creditors ❑ ~_qg ❑ 50-99 ❑ 100-199 ❑ 200-999 ■ 1,000-5,000 ❑ 5001-10,000 ❑ 10,001-25,000 ❑ 25,001-50,000 ❑ 50,001-100,000 ❑Morethan100,000 15. Estimated Assets ❑ $0 - $50,000 ❑ $50,001 - $100,000 ❑ $100,001 - $500,000 ❑ $500,001 - $1 million ❑ $1,000,001 - $10 million ❑ $10,000,001 - $50 million ❑ $50,000,001 - $100 million ❑ $100,000,001 - $500 million ❑ $500,000,001 - $1 billion ■ $1,000,000,001 - $10 billion ❑ $10,000,000,001 - $50 billion ❑More than $50 billion 16. Estimated liabilities ❑ $0 - $50,000 ❑ $50,001 - $100,000 ❑ $100,001 - $500,000 ❑ $500,001 - $1 million ❑ $1,000,001 - $10 million ❑ $10,000,001 - $50 million ❑ $50,000,001 - $100 million ❑ $100,000,001 - $500 million ■ $500,000,001 - $1 billion ❑ $1,000,000,001 - $10 billion ❑ $10,000,000,001 - $50 billion ❑More than $50 billion Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 3 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 4 of 24 Main Document Pg Case number (if known) Purdue Pharma L.P. _ Request for Relief, Declaration, and Signatures WARNING -- Bankruptcy fraud is a serious crime. Making a false statement in connection with a bankruptcy case can result in fines up to $500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571. 17. Declaration and signature of authorized representative of debtor The debtor requests relief in accordance with the chapter of title 11, United States Code, specified in this petition. have been authorized to file this petition on behalf of the debtor. have examined the information in this petition and have a reasonable belief that the information is true and correct. declare under penalty of perjury that the foregoing is true and correct. Executed on X `~ Signature of authorized representative of debtor Title 18. Signature of attorney September 15, 2019 M M / DD / YWY Jon Lowne Printed name Authorized Person Date September 15, 2019 IJiI~Il~7~7~~~~i X ~~' Signature of attorney for debtor Marshall S. Huebner Printed name Davis Polk &Wardwell LLP Firm name 450 Lexington Avenue New York, NY 10017 Number, Street, City, State &ZIP Code Contact phone 212-450-4000 Email address Purdue.noticing~dpw.com 2607094 NY Bar number and Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 4 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 5 of 24 Main Document SCHEDULE 1 TO PETITION Pending Bankruptcy Cases in the Southern District of New York Filed by the Debtor and Affiliates of the Debtor On the date hereof, each of the affiliated entities listed below (including the debtor in this chapter 11 case) filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York (the "Court"). A motion has been filed with the Court requesting that the chapter 11 cases of these entities be consolidated for procedural purposes only and jointly administered under the case number assigned to the chapter 11 case of Purdue Pharma L.P. 1. Purdue Pharma L.P. 2. Purdue Pharma Inc. 3. Purdue Transdermal Technologies L.P. 4. Purdue Pharma Manufacturing L.P. 5. Purdue Pharmaceuticals L.P. 6. Imbrium Therapeutics L.P. 7. Adlon Therapeutics L.P. 8. Greenfield BioVentures L.P. 9. Seven Seas Hill Corp. 10. Ophir Green Corp. 1 1. Purdue Pharma of Puerto Rico 1 2. Avrio Health L.P. 1 3. Purdue Pharmaceutical Products L.P. 14. Purdue Neuroscience Company l 5. Nayatt Cove Lifescience Inc. 16. Button Land L.P. 1 7. Paul Land Inc. 18. Quidnick Land L.P. 19. Rhodes Associates L.P. 20. Rhodes Pharmaceuticals L.P. 2l.Rhodes Technologies 22. UDF LP 23. SVC Pharma LP 24. SVC Pharma Inc. Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 6 of 24 Main Document PURDUE PHARMA INC. SECRETARY'S CERTIFICATE September 15, 2019 I,Marc L. Kesselman,the Secretary ofPurdue Pharma Inc., a New York corporation ("PPI"), hereby certify, in my capacity as the Secretary ofPPI and not individually, that the resolutions attached as Annex A were duly approved by the Board of Directors ofPPI on September 15,2019, have not been amended, modified, revoked or rescinded as ofthe date hereof, and are in full force and effect. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] #92438815v2 Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 7 of 24 Main Document IN WITNESS WHEREOF,the undersigned, solely in his capacity as the Secretary of PPI, and not individually, has executed this Certificate as of the date first written above. PURDUE PHARMA INC. By: Name: March . Kesse an Title: Senior Vice President, General Counsel &Secretary [SignatzcNe Page to Secretary's Certificate] /l92438815v2 Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 8 of 24 Annex A Resolutions [See attached.] lk92438815v2 Main Document Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 9 of 24 Main Document Pg Purdue Pharma Inc. Resolutions of the Board of Directors September 15, 2019 Commencement of Chapter 11 Case WHEREAS,(i) the Corporation is the general partner of Purdue Pharma L.P., a Delaware limited partnership ("PPLP"), and the general partner or managing general partner of each entity identified on Schedule 1 A hereto, and (ii) PPLP is a limited partner or partner of each entity identified on Schedule lA hereto (other than Rhodes Pharmaceuticals L.P. ("Rhodes Phanna LP"), Rhodes Technologies("Rhodes") and UDF L.P.("UDF"))• ~ WHEREAS,(i) Rhodes Associates L.P.("Rhodes LP") is(A)the general partner of each entity identified on Schedule 1B hereto and (B) a limited partner of Rhodes Pharma LP and a partner of Rhodes, and (ii) Rhodes is a limited partner of UDF; WHEREAS, each of PPLP, each entity identified on Schedule lA and each entity identified on Schedule 1 B is hereafter referred to as a "Partnership" and collectively, the "Partnerships"; WHEREAS the Board reviewed and considered the materials presented by the management team and the financial and legal advisors of each Partnership regarding the liabilities and liquidity of each Partnership, the strategic alternatives available to each of them and the impact of the foregoing on the Partnerships' respective businesses; and WHEREAS the Board consulted with each Partnership's management team and its financial and legal advisors, and has fully considered each of the Partnerships' strategic alternatives. NOW, THEREFORE, BE IT RESOLVED that in the judgment of the Board, it is desirable and in the best interests of(i) the Corporation,(ii) PPLP (in the Corporation's capacity as general partner of PPLP)and (iii) each of the other Partnerships (in the Corporation's capacity as general partner of certain of such Partnerships, or in its capacity as general partner of an entity that is directly or indirectly the general partner, limited partner or partner of certain of such Partnerships), and (iii) the respective creditors and other stakeholders of each of the foregoing, that a petition be filed by the Corporation and each of the Partnerships seeking relief under the provisions of chapter 11 of title 11 of the United States Code (the "Bankruptcy Code"); and Additional conformed resolutions needed for the Boards of(A)Nayatt Cove Lifescience Inc.,(B)Paul Land [nc.,(C)SVC Pharma Inc.(covering the Ch. 1 1 filing of itself, and of SVC Pharma LP in its capacity as the general partner of SVC Pharma LP),(D)Seven Seas Hill Corp. and (E) Ophir Green Corp.(the latter two are BVI entities, and these resolutions should cover the Ch. 11 filing for each BVI entity and also each authorize the Ch. 1 1 filing for Purdue Pharma of Puerto Rico, a DE general partnership, of which each BVI entity is a 50% partner). a9za33 i; i ~z 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 10 of 24 Main Document Pg RESOLVED FURTHER, that each of the Chief Executive Officer, Chief Financial Officer or any other officer or duly authorized signatory of the Corporation (each, an "Authorized Person") be, and each of them hereby is, authorized on behalf of(i) the Corporation, (ii) PPLP (in the Corporation's capacity as general partner of PPLP) and (iii) each of the other Partnerships (in the Corporation's capacity as general partner of certain of such Partnerships, or in its capacity as general partner of an entity that is directly or indirectly the general partner, limited partner or partner of certain of such Partnerships), to execute and verify petitions under chapter 11 of the Bankruptcy Code and to cause such petitions to be filed in the United States Bankruptcy Court for the Southern District of New York (the "Court"), each such petition to be filed at such time as the Authorized Person executing the petition shall determine and to be in the form approved by the Authorized Person executing such petition, such approval to be conclusively evidenced by the execution, verification and filing thereof. Retention of Advisors RESOLVED,that the Authorized Persons be, and hereby are, authorized, empowered and directed to employ, subject to Bankruptcy Court approval: (i) the law firm of Davis Polk & Wardwell LLP as general bankruptcy counsel, (ii) PJT Partners LP as investment banker, (iii) AlixPartners LLP as restructuring financial advisor,(iv) Prime Clerk LLC as notice, claims and solicitation agent, and (v) any other legal counsel, accountants, financial advisors, restructuring advisors or other professionals any of the Authorized Persons deems necessary, appropriate or advisable; each to represent and assist the Corporation and each Partnership in carrying out their respective duties and responsibilities and exercising their respective rights under the Bankruptcy Code (including, but not limited to, the law firms filing any pleadings or responses); and in connection therewith, each of the Authorized Persons be, and hereby is authorized, empowered and directed, in accordance with the terms and conditions hereof, to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed appropriate applications for authority to retain such services; and RESOLVED FURTHER, that each of the Authorized Persons, be, and hereby is, authorized, empowered and directed to execute and file all petitions, schedules, motions, lists, applications, pleadings, and other papers, and to perform such further actions and execute such further documentation that such Authorized Person deems necessary, appropriate or desirable in accordance with theseresolutions. General Authorization and Ratification RESOLVED that the Authorized Persons be, and each of them hereby is, authorized, directed and empowered, in the name and on behalf of (i) the Corporation, (ii) PPLP (in the Corporation's capacity as general partner of PPLP)and (iii) each of the other Partnerships (in the Corporation's capacity as general partner of certain of such Partnerships, or in its capacity as general partner of an entity that is directly or indirectly the general partner, limited partner or partner of certain of such Partnerships), to take, or cause to be taken, any and all further actions (including, without limitation,(i) execute, deliver, certify, file and/or record and perform any and all documents, agreements, instruments, motions, affidavits, applications for approvals or rulings of governmental or regulatory authorities or certificates and (ii) pay fees and expenses in connection with the transactions contemplated by the foregoing resolutions) and to take any and 2 #92433131 v2 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 11 of 24 Main Document Pg all steps deemed by any such Authorized Person to be necessary, advisable or desirable to carry out the purpose and intent of each of the foregoing resolutions, and all actions heretofore taken by any such Authorized Person or the Board in furtherance thereof are hereby ratified, confirmed and approved in all respects; and RESOLVED FURTHER, that all acts, actions, and transactions relating to the matters contemplated by the foregoing resolutions done in the name of and on behalf of (i) the Corporation, (ii) PPLP (in the Corporation's capacity as general partner of PPLP) and (iii) each of the other Partnerships (in the Corporation's capacity as general partner of certain of such Partnerships, or in its capacity as general partner of an entity that is directly or indirectly the general partner, limited partner or partner of certain of such Partnerships), which acts would have been approved by the foregoing resolutions except that such acts were taken before the adoption of these resolutions, are hereby in all respects approved and ratified as the true acts and deeds of the Corporation and the Partnerships, as applicable, with the same force and effect as if each such act, transaction, agreement, or certificate has been specifically authorized in advance by resolution of the Board; and RESOLVED FURTHER, that the omission from these resolutions of any agreement, document or other arrangement contemplated by any of the agreements, documents or instruments described in the foregoing resolutions or any action to be taken in accordance with any requirement of any of the agreements or instruments described in the foregoing resolutions shall in no manner derogate from the authority of the Authorized Persons to take all actions necessary, desirable, advisable or appropriate to consummate, effectuate, carry out or further the transactions contemplated by, and the intent and purposes of, the foregoing resolutions. 3 #92433131v2 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 12 of 24 Main Document Schedule lA ENTITY JURISDICTION OF FORMATION Purdue Transdermal Technologies L.P. Delaware Purdue Pharma Manufacturing L.P. Delaware Purdue Pharmaceuticals L.P. Delaware Imbrium Therapeutics L.P. Delaware Adlon Therapeutics L.P. Delaware Greenfield BioVentures L.P. Delaware Avrio Health L.P. Delaware Purdue Pharmaceutical Products L.P. Delaware Purdue Neuroscience Company Delaware Rhodes Associates L.P. Delaware Rhodes Pharmaceuticals L.P. Delaware Rhodes Technologies Delaware UDF L.P. Delaware Schedule 1B #92433131v2 ENTITY JURISDICTION OF FORMATION Button Land L.P. Delaware Quidnick Land L.P. Delaware Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 13 of 24 Main Document DAMS POLK & WARDWELL LLP 450 Lexington Avenue New York, New York 10017 Telephone:(212)450-4000 Facsimile:(212) 701-5800 Marshall S. Huebner Benjamin S. Kaminetzky Timothy Graulich Eli J. Vonnegut Proposed Counsel to the Debtors and Debtors in Possession UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re: Chapter 11 PURDUE PHARMA L.P., et al., Case No. 19-[ Debtors. ~ ](RDD) (Joint Administration Pending) CONSOLIDATED CORPORATE OWNERSffiP STATEMENT PURSUANT TO FEDERAL RULES OF BANKRUPTCY PROCEDURE 1007 AND 7007.1 Pursuant to Rules 1007(a)(1), 1007(a)(3) and 7007.1 of the Federal Rules of Bankruptcy Procedures (the "Bankruptcy Rules") and Rule 1007-3 of the Local Bankruptcy Rules for the Southern District of New York (the "Local Rules"), Purdue Pharma L.P. ("PPLP") and its affiliates that are debtors and debtors in possession (collectively, the "Debtors") respectfully represent: t The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P.(7484), Purdue Pharma Inc.(7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp.(4591), Ophir Green Corp.(4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P.(4140), Purdue Pharmaceutical Products L.P.(3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P.(7502), Rhodes Associates L.P.(N/A), Paul Land Inc.(7425), Quidnick Land L.P.(7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901. Pg 19-23649 1. Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 14 of 24 Main Document Non-Debtor Pharmaceutical Research Associates L.P. directly owns 100% of the ownership interests of PPLP. Non-Debtor PLP Associates Holdings L.P. directly owns approximately 99.5061% of the ownership interests of Pharmaceutical Research Associates L.P. Non-Debtor BR Holdings Associates L.P. directly owns 100% of the ownership interests of PLP Associates Holdings L.P. Non-Debtor Beacon Company and non-Debtor Rosebay Medical Company L.P. each directly own 50% ofthe ownership interests of BR Holdings Associates L.P. Non-Debtor Heatheridge Trust Company Limited, as Trustee under Settlement dated 31 December 1993 directly owns 100% of the ownership interests of Beacon Company. Richaxd S. Sackler, M.D.("RSS") and Jonathan D. Sackler ("JDS"), as Trustees under Trust Agreement dated November 5, 1974 directly own 98% of the ownership interests of Rosebay Medical Company L.P. To the best of the Debtors' knowledge and belief, no other person or entity directly or indirectly owns 10% or more ofthe ownership interests ofPPLP. 2. Non-debtor Banela Corporation directly owns 50% of the ownership interests of Debtor Purdue Pharma Inc. ("PPI"); non-debtor Linarite Holdings LLC directly owns 25% of the ownership interests of PPI; and non-debtor Perthlite Holdings LLC directly owns 25% of the ownership interests of PPI. Non-debtor Millborne Trust Company Limited, as Trustee of the Hercules Trust under Declaration of Trust dated 2 March 1999 directly owns 100% of the ownership interests of Banela Corporation. Non-debtor Data. LLC, as Trustee under Trust Agreement dated December 23, 1989 directly owns 100% of the ownership interests of Linarite Holdings LLC. Non-debtor Cornice Fiduciary Management LLC, as Trustee under Trust Agreement dated December 23, 1989 directly owns 100% of the ownership interests of Perthlite Holdings LLC. To the best of the Debtors' knowledge and belief, no other person or entity directly or indirectly owns 10% or more of the ownership interests of PPI. 2 Pg 19-23649 3. Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 15 of 24 Main Document PPLP directly owns 100% of the ownership interests of the following Debtors: Purdue Transdermal Technologies L.P., Purdue Pharmaceuticals L.P., Purdue Pharma Manufacturing L.P., Adlon Therapeutics L.P., Imbrium Therapeutics L.P., Greenfield BioVentures L.P., Nayatt Cove Lifescience Inc., Purdue Pharmaceutical Products L.P., Rhodes Associates L.P., Avrio Health L.P., Seven Seas Hill Corp., and Ophir Green Corp. PPLP directly owns 99% of the ownership interests of Debtor Purdue Neuroscience Company. Purdue Pharma Inc. directly owns the remaining 1% of the ownership interests of Purdue Neuroscience Company. 4. Rhodes Associates L.P. directly owns 100% of the ownership interests of the following Debtors: Rhodes Technologies, Rhodes Pharmaceuticals L.P. and Paul Land Inc. 5. Rhodes Technologies directly owns 100% of the ownership interests of UDF L.P. and SVC Pharma Inc. 6. UDF LP directly owns 100% of the ownership interests of Button Land L.P. and Quidnick Land L.P. UDF LP directly owns 99% of the ownership interests of SVC Pharma LP SVC Pharma Inc. directly owns 1% of the ownership interests ofSVC Pharma LP. 7. Seven Seas Hill Corp. and Ophir Green Corp. each directly own 50% of the ownership interests of Purdue Pharma of Puerto Rico. 8. Attached hereto as Exhibit A is an organizational chart reflecting the Debtors' ownership structure. 3 Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 16 of 24 Exhibit A Main Document Pg 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 17 of 24 Main Document Pg PURDUE PHARMA L.P. -SUBSIDIARIES Purdue Pharma Inc., a New YorA corporation Purdue Pharma L.P., a velaware limited partnership ~ L 0%• 100% Purdue Pharma Inc., a New York corporation 1 00% Rhodes Associates L.P., a Delaware limited pa~lnership 100 0%~ 100% 100% 0%'• Paul Land Inc., a New York corporation Rhodes Technologies, a Delaware general parmership ~~~ 100% Rhodes Phannaceuticals L.P., 100% 100 SVC Pharma Inc., a Delaware corporation Button Land L.P., a Delaware limited partnership l00% Nayatt Cove Lifescience Inc., a Dzlaware corporation 1% 99% 100% Adlon Thcrapcmics L.P., a Uelaxarc limi~ul panncrship a Delaware limited partnership UDF LP, a Delaware limited partnership 0%' Nurduc Transdcnnal Technologies L.P., a Ucla~rarc limited pannarship Purdue Pharma Inc., a Nzw York corporation Purdue Pharma Inc., a New York corporation Purdue Pharma Inc., a New York corporation SVC Pharma LP, a Delaware limited partnership ~iei ~~~ Quidnick Land L.P., a Delaware limited partnership goo/ Seven Seas Hill Corp. (British Virgin Islands) 0%' Purdua Pharma Inc., a New York corporation i/ Purdue Neuroscience Company, a Dzlaware general partnership Ophir Green Corp. (British Virgin Islands) 0%' 50% Purdue Pharma Inc., a New York corporation IOa°„ 50% Purdue Pharma of Puerto Rico, a Delaware gentral parmzrship A~rio Health L.P., a Delaware limited partnership (Formerly Purdue Products L.P. ~ l uu% py,+~ Purduz Pharmaceutical Products L.P., a Delaware limired parmership General Panner has no equity in[erest in L.P., rather the General Partner receives a service fee for acting as General Partner. Purdue Pharmaccwicals L.P., a Delaware limited pannuship hnbrium Therapeutics L.P.. a Dela~~arc limitd pannership Purdue Phanna Manufacmnng L.P.. a Dclaxarc linuWd panncrship Gmcnficld BioVcnluras L.P., a Delauarc limned parmers6ip 19-23649 Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 18 of 24 Main Document Pg PURDUE PHARMA L.P.-OWNERSHIP Millborne Trust Company Limited, as 1'rustae of the Hercules 'f rust under Declaration of Trust datad 2 March 1999 Cornice Fiduciary Management LLC, as Trustze under Trust Agreement datzd ~ December _3, 1989 (1989 Trust 4) Daia LLC,as Trustee under Trust Abreemem dated December 23, 1989(1989 Trust 3) lieatheridge Trust Compa~iy Limited, as Trustee under Settlement dated 31 December 1993 100oa / 100% Cornice Fiduciary Management LLC, as Trustee under Trust Agreement dated December 23, 1989(1989 Trust 2) Data LLC, as ~Prustee under Trust Agreement dated December 23, 1989(1989'I'rust I) 50% 100% Banela Corporation (British Virgin Islands) 100% 100% Linarite Holdings LLC, a Delaware limited liability company Perthlite Holdings LLC, a Delawara limited liability company 50% Stanhope Gate Corp. (British Virgin Islands) Richard S. Sackler, M.D.("RSS")and Jonathan D. Sackler f'JDS"), as Trustees under Trust Agrnzment datzd November 5, 1974 Rosebay Medical Company, Inc., a Delaware corporation(GP) p/o 2% 50% Z5~ Beacon Company, a Delaware general partnership 25% 98% r Rosebay Medical Company L.N., a Dzlaware limited partnership BR Holdings Associates Inc., a New York corporation Same ultimatz bzneficial ownership as Purdue Pharma Inc. ~ u"~, 0%* PLP Associates Holdings Inc., a New York corporation BR Holdings Associates L.P., a Dalaware limited partnership 0°h' Purdue Phanna Inc., a New York corporation 100 PLP Associates Holdings L.P., a Delaware limited partnership 0.2475%" 50 99.5061%" PLP Associates Holdings Inc., a New York corporation 0.2464%#• BR Holdings Associates Inc., a New York corporation 0%• Pharmaceutical Research Associates L.P., a Delaware limited partnership*** o~• ioor Purdue Pharma L.P., a Delaware limited partnership General Partner has no equity interest in L.P., rather the General Penner receives a service fee for acting as General Partner. " BR Holdings Associates Inc. is the general partner of Pharmaceutical Research Associates L.P.; Purdue Pharma Inc., PLP Associates Holdings Inc. and PLP Associates Holdings L.P. are the limited partners of Pharmaceutical Research Associates L.P. •••Name change from Purdue Holdings L.P. to Pharmaceutical Research Associated L.P. effective July 24, 2018 19-23649 Debtor name Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 19 of 24 Main Document Pg Purdue Pharma L.P. United States Bankruptcy Court for the: Southern District of New York ❑ Check if this is an amended filing Case number (if known) Official Form 204 Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims and Are Not Insiders 12/15 A list of creditors holding the 50 largest unsecured claims must be filed in a Chapter 11 or Chapter 9 case. Include claims which the debtor disputes. Do not include claims by any person or entity who is an insider, as defined in 11 U.S.C.§ 101(31). Also, do not include claims by secured creditors, unless the unsecured claim resulting from inadequate collateral value places the creditor among the holders of the 50 largest unsecured claims. Certain of the Debtors are named as defendants in over 2,600 actions across the country in connection with the marketing and sale of opioid medications ("Pending Actions"). Any claims asserted against any Debtor in respect of the Pending Actions (the "Pending Action Claims") are contingent, unliquidated in amount and disputed. All creditors asserting Pending Action Claims will be included in the Debtors' list of creditors. This List of Creditors Who Have the 50 Largest Unsecured Claims and Are Not Insiders does not include these contingent, unliquidated and disputed claims. Name of creditor and complete mailing address, including zip code Name, telephone number, and email Nature of the claim (for example, trade address of creditor contact debts, bank loans, professional services, and government contracts) Indicate if claim is contingent, unliquidated, or disputed Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim. Total claim, if Deduction for partially value of collateral or secured setoff ~ 3 4 5 Unsecured claim PENSION BENEFIT GUARANTY CORPORATION CYNTHIA WONG 1200KSTREETNW ASHINGTON, DC 20005 ENSIONBENEFITGUARANIYCORPORATION nN:CYNTHIA WONG HONE:202-229-3033 /1X: 202-326-4112 MAIL: WONG.CYNTHIA@PBGC.GOV PENSION CVS CAREMARK PART D SERVICES, L.L.C. NDY ZANIN, TRADE DIRECTOR, MED D 1 CVS DRIVE WOONSOCKET, RI 02895 VS CAREMARK PART D SERVICES, L.L.C. TTN: ANDY ZANIN, TRADE DIRECTOR, MED D HONE:440-542-4010 MAIL: ANDREW.ZANIN@CVSHEALTH.COM PAYER REBATES 519,281,161 OPTUMRX, INC. KENT ROGERS, SENIOR VP INDUSTRY RELATIONS 2300 MAIN ST IRVINE, CA 92614-6223 PTUMRX, INC. TTN: KENT ROGERS,SENIOR VP INDUSTRY ELATIONS HONE: 949-988-6066 MAIL: KENT.ROGERS@OPTUM.COM PAYER REBATES $15,800,513 DEFENSE HEALTH AGENCY COLONEL DAVID BOBB, CHIEF PHARMACY OPERATIONS DIVISION, DHA 16401 E CENTRETECH PKWY URORA, C080011-9066 EFENSE HEALTH AGENCY TTN: COLONEL DAVID 0088, CHIEF PHARMACY PERATIONS DIVISION, DHA HONE: 703-681-2890 MAIL: DAVID.W.BOBB.CIV@MAIL.MIL PAYER REBATES 55,952,016 PAYER REBATES 55,162,762 PAYER REBATES 55,039,745 DEPARTMENT OF HEALTH CARE SERVICES(CA) DEPARTMENT OF HEALTH CARE SERVICES(CA) TTN: ROBERT SHUN ROBERT SHUN HONE: 916-552-9609 PO BOX 997413 MAIL: ROBERT.SHUN@DHCS.CA.GOV SACRAMENTO, CA 95899-7413 CAREMARKPCS HEALTH, L.L.C. APPAN BHATT, DIRECTOR TRADE RELATIONS 1 CVS DRIVE WOONSOCKET, RI 02895 Official Form 204 A REMARKPCS HEALTH, L.L.C. ~N:SAPPAN BHATT, DIRECTOR TRADE ELATIONS HONE:847-559-3062 MAIL: SAPPAN.BHATT@CVSHEALTH.COM CONTINGENT UNLIQUIDATED Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims UNDETERMINED page 1 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 20 of 24 Main Document Pg Case number (if known) Purdue Pharma L.P. Name Name of creditor and complete mailing address, including zip code Name, telephone number, and email address of creditor contact Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts) Indicate if claim is contingent, unliquidated, or disputed Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. if claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim. Total claim, if partially secured MERISOURCEBERGEN DAVE VIETRI, VICE PRESIDENT BRANDED AND PECIALTY CONTRACTS 3735 GLEN LAKE DR CHARLOTTE, NC 28208 ~ MERISOURCEBERGEN TTN: DAVE VIETRI, VICE PRESIDENT BRANDED ND SPECIALTY CONTRACTS HONE:610-727-7310 MAIL: DVIETRI@AMERISOURCEBERGEN.COM Deduction for value of collateral or setoff Unsecured claim DISTRIBUTOR FEES 54,455,373 ORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES TTN:JOHN STANCIL HONE:919-855-4305 MAIL:IOHN.STANCIL@DHHS.NC.GOV PAYER REBATES $3,703,227 CKESSON CORPORATION TTN: CHRIS ALVERSON,SENIOR VICE PRESIDENT F SUPPLY CHAIN MANAGEMENT H ON E:972-446-4104 MAIL: CHRIS.ALVERSON@MCKESSON.COM DISTRIBUTOR FEES $3,655,581 1 O CARDINAL HEALTH EFF CIZL, DIRECTOR STRATEGIC SOURCING NATIONAL BRANDS 1330 ENCLAVE PKY HOUSTON,TX 77077-2025 ARDINAL HEALTH TTN: JEFF CIZL, DIRECTOR STRATEGIC SOURCING NATIONAL BRANDS HONE:614-757-3694 EMAIL: JEFF.CIZL@CARDINALHEALTH.COM DISTRIBUTOR FEES $3,465,979 ~ ~ MISSOURI HEALTHNET DIVISION CAROLINA DELAROCHA PO BOX 570 EFFERSON CITY, MO 65102 MISSOURI HEALTHNET DIVISION TTN: CAROLINA DELAROCHA PHONE: 573-526-5664 MAIL: CAROLINA.D.DELAROCHA@DSS.MO.GOV pgYER REBATES $3,172,515 SCENT HEALTH SERVICES LLC TTN: EDWARD ADAMCIK, PRESIDENT ASCENT EALTH SERVICES HONE: 908-240-1537 MAIL: EADAM CI K@ASCE NTH EALTHS ERV IC ES.COM PAYER REBATES $2,798,697 ISCONSIN DEPARTMENT OF HEALTH SERVICES 1TN: KIM WOHLER HONE:608-267-7100 EMAIL: KIM.WOHLER@WISCONSIN.GOV PAYER REBATES $2,021,937 TATE OF NEW YORK DEPARTMENT OF HEALTH TTN: CHRISTOPHER DESORBO HONE: 518-402-0836 MAIL: HRISTOPHER.DESORBO@HEALTH.NY.GOV PAYER REBATES 51,963,959 PAYER REBATES $1,614,986 PRIME THERAPEUTICSLLC TTN:JOSH BAST, SENIOR DIRECTOR HARMACEUTICALTRADE RELATIONS HONE:612-777-5621 MAIL: JABAST@PRIMETHERAPEUTICS.COM PAYER REBATES 51,533,047 HIO DEPARTMENTOF MEDICAID TTN: TRACEY ARCHIBALD PHONE:614-752-3522 MAIL: RACEY.ARCHIBALD@ MEDICAID.OHIO.GOV PAYER REBATES $1,478,682 NORTH CAROLINA DEPARTMENT OF HEALTH N D HUMAN SERVICES OHN STANCIL 2001 MAIL SERVICE CENTER RALEIGH, NC 27699-2000 $ MCKESSON CORPORATION CHRIS ALVERSON, SENIOR VICE PRESIDENT OF SUPPLY CHAIN MANAGEMENT ON E POST ST SAN FRANCISCO, CA 94104-5203 9 ~2 SCENT HEALTH SERVICES LLC EDWARD ADAMCIK, PRESIDENT ASCENT HEALTH SERVICES 1209 ORANGE ST I LMINGTON, DE 19801 13 WISCONSIN DEPARTMENT OF HEALTH ERVICES KIM WOHLER 313 BLETHER RD MADISON, WI 53784 TATE OF NEW YORK DEPARTMENT OF 14 HEALTH CHRISTOPHER DESORBO RIVERVIEW CENTER 150 BROADWAY SUITE 355 LBANY, NY 12204-2719 ~5 TATE OF NEW JERSEY DIVISION OF MEDICAL TATE OF NEW JERSEY DIVISION OF MEDICAL SSISTANCE AND HEALTH SERVICES SSISTANCE AND HEALTH SERVICES TTN: DAVID WILLIAMS DAVID WILLIAMS PHONE:609-588-7395 LOCKBOX 655 MAIL: DAVID.R.WILLIAMS@DHS.STATE.NJ.US RENTON, NJ 08646-0655 16 PRIME THERAPEUTICSLLC OSH BAST, SENIOR DIRECTOR PHARMACEUTICAL TRADE RELATIONS PO BOX 64812 T PAUL, MN 08646-0655 ~ ~ OHIO DEPARTMENT OF MEDICAID RACEY ARCHIBALD 345 N. LINCOLN BLVD. OKLAHOMA CITY, OK 73105 O~cial Form 204 Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims page 2 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 21 of 24 Purdue Pharma L.P. Main Document Pg Case number (if known) Name Name of creditor and complete mailing address, including zip code Name, telephone number, and email address of creditor contact Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts) Indicate if claim is contingent, unliquidated, or disputed Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim. Total claim, if partially secured ~$ COMMONWEALTH OF PENNSYLVANIA MEDICAID DRUG REBATE PROGRAM BRITTANY STARR PO BOX 780634 PHILADELPHIA, PA 19178 ~ 9 GEORGIA DEPT OF COMMUNITY HEALTH REBECCA MORRISON MEDICAID DRUG REBATE PROGRAM TLANTA, GA 30384-8194 ~ SYNEOS HEALTH fka INVENTIV HEALTH HAIYAN WANG, DIRECTOR BUSINESS DEVELOPMENT, EARLY PHASE 1030 SYNC ST MORRISVILLE, NC 27560 21 RHODES TECHNOLOGIES INC EDWARD MAHONY 201TRESSER BOULEVARD TAMFORD, CT 06901 2 OHIO CIINICALTRIAL5INC G LEN APSELOFF 1380 EDGEHILI RD COLUMBUS,OH 43212 OMMONWEALTH OF PENNSYLVANIA MEDICAID RUG REBATE PROGRAM TTN: BRITTANY STARR HONE: 717-346-8164 EMAIL: C-BSTARR@PA.GOV Deduction for value of collateral or setoff Unsecured claim PAYER REBATES $1,442,635 EORGIA DEPT OF COMMUNITY HEALTH TTN: REBECCA MORRISON HONE: 404-657-7239 MAIL: REBECCA.MORRISON@DCH.GA.GOV PAYER REBATES 51,414,770 YNE05 HEALTH fka INVENTIV HEALTH TTN: HAIYAN WANG, DIRECTOR BUSINESS EVELOPMENT, EARLY PHASE HONE: 514-485-7579 AX: 919-876-9360 TRADE DEBT $1,073,469 HODES TECHNOLOGIES INC TfN: EDWARD MAHONY HONE: 203-588-7088 MAIL: EDWARD.MAHONY@TXPSVCS.COM SERVICES FEES $1,034,752 HIO CLINICALTRIALS INC TTN:GLEN APSELOFF HONE:614-754-1570 EMAIL: GLEN@OHIOCLINICALTRIALS.COM TRADE DEBT $600,000 TRADE DEBT $522,334 PAYER REBATES $400,586 23 PPD DEVELOPMENT LP STEPHEN SCALDAFERRI 26361 N ETWO RK PL CHICAGO, IL 60673 PD DEVELOPMENT LP TTN:STEPHEN SCALDAFERRI HONE:910-465-7800 MAIL: STEPHEN.SCALDAFERRI@PPDI.COM 24 OKIAHOMA HEALTH CARE AUTHORITY STACEY HALE PO BOX 18968 OKLAHOMA CITY, OK 73154-0299 KLAHOMA HEALTH CARE AUTHORITY TTN:STACEY HALE HONE:405-522-7453 MAIL: STACEY.HALE@OKHCA.ORG 25 PHARMACEUTICAL RESEARCH ASSOC INC OSEPH DAWN 130 PARKLAKE AVE STE 400 RALEIGH, NC 27612 HARMACEUTICAL RESEARCH ASSOC INC TTN: JOSEPH DAWN HONE:434-951-3208 MAIL: JOSEPHDAWN@PRAHS.COM TRADE DEBT $373,122 26 WAVELENGTH ENTERPRISES INC RAYMOND ALSKO 1700 RTE 23 N STE 130 FIRST FL WAYNE, NJ 07470 AVELENGTH ENTERPRISES INC ~N: RAYMOND ALSKO HONE:973-832-9260 MAIL: AYMON D.ALSKO@ WAVELENGTHPHARMA.COM TRADE DEBT $361,909 2~ CONTRACTPHARMACALCORP NTHONYGARGANO 135 ADAMS AVE HAUPPAUGE, NY 11785-3633 ONTRACTPHARMACALCORP TTN:ANTHONYGARGANO HONE:631-231-4610 MAIL: ANTHONY.GARGANO@CPC.COM TRADE DEBT $327,422 TRADE DEBT $271,195 28 PL DEVELOPMENT LLC SINGLEfERRY 609-2 CANTIAGUE ROCK RD ESTBURY, NY 11590 Official Form 204 L DEVELOPMENT LLC TTN:1 SINGLEfERRY HONE: 516-986-1700 EMAIL: JSINGLETERRY@PLDEVELOPMENTS.COM Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims page 3 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 22 of 24 Main Document Pg Case number (if known) Purdue Pharma L.P. Name Name of creditor and complete mailing address, including zip code Name, telephone number, and email address of creditor contact Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts) Indicate if claim is contingent, unliquidated, or disputed Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim. Total claim, if partially secured Deduction for value of collateral or setoff Unsecured claim 29 HEALTHCORE INC KELSEY GANGEMI 123 JUSTISON ST STE 200 ILMINGTON, DE 19801 EALTHCORE INC TTN: KELSEY GANGEMI HONE: 302-230-2000 MAIL: KGANGEMI@HEALTHCORE.COM TRADE DEBT 5269,621 3O COGNIZANT TECH SOLUTIONS US CORP U RANIAN KAYAL 24721 NETWORK PL CHICAGO, IL 60673 OGNIZANTTECH SOLUTIONS US CORP TTN:SURANJAN KAYAL HONE: 201-744-3444 MAIL SURANIAN.KAYAL@COGNIZANT.COM TRADE DEBT $262,216 31 WgLRUS LLC ALRUS LLC TTN: PAULA BUCHMA HONE:646.731.1701 MAIL: PAULA@WALRUSNYC.COM TRADE DEBT $236,471 TRADE DEBT $235,742 EMERSON GROUP INC TTN: MATT POLI HONE:610-971-9600 MAIL: MATT.POLI@EMERSONGROUP.COM TRADE DEBT $234,029 NTEGRATED BEHAVIORAL HEALTHINC TTN: MARY SWEET HONE:617-765-3144 MAIL: MSW EET@ IN FLEXX ION.CO M TRADE DEBT 5228,793 TRADE DEBT 5210,841 PECGX LLC TTN:GENERAL000NSEL HONE: 314-654-2000 AX:800-323-5039 TRADE DEBT 5189,371 CI HEALTH TTN:MARGARETSHUBNY HONE: 312.596.2648 MAIL: MARGARET.SHUBNY@GCIHEALTH.COM TRADE DEBT $161,049 RIALCARD INC TTN: LINDSEY DOBBINS HONE: 919-415-5494 MAIL: LINDSEY.DOBBINS@TRIALCARD.COM TRADE DEBT 5151,286 URPLE STRATEGIES LLC TAN: SARAH SIMMONS PHONE: 703-548-7877 MAIL: ARAH.SIMMONS@PU RPLESTRATEGIES.COM TRADE DEBT $150,000 PAULA BUCHMA 18 E 17TH ST 4TH FL NEW YORK, NY 10003 32 DENVER HEALTH &HOSPITALAUTH COTT HOYE, GENERAL COUNSEL 777 BANNOCK STREET DENVER, CO 80204 33 EMERSON GROUP INC MATT POLI 07 EAST LANCASTER AVE AYNE, PA 19087 34 INTEGRATED BEHAVIORAL HEALTHINC MARY SWEET 3070 BRISTOL ST STE 350 COSTA M ESA, CA 92626 35 CHALLENGE PRINTING COMPANY . YOUNG PO BOX 27775 N EWARK, NJ 07101-7775 36 pECGX LLC ENERALCOUNSEL 385 MARSHALL AVE AINT LOUIS, MO 63119-1831 3~ GCI HEALTH MARGARETSHUBNY PO BOX 101890 TLANTA, GA 30392 38 RIALCARD INC LINDSEY DOBBINS 2250 PERIMETER PARK DR STE 300 MORRISVILLE, NC 27560 39 PURPLE STRATEGIES LLC SARAH SIMMONS 15 SLATERS LN LEXANDRIA, VA 22314 Official Form 204 ENVER HEALTH &HOSPITALAUTH TTN:SCOTT HOVE, GENERAL COUNSEL PHONE: 303-436-6000 AX:303-602-4934 HALLENGE PRINTING COMPANY TTN: 5. YOUNG HONE: 973-471-4700 EMAIL: SYOUNG@CHALLENGEPRINTINGCO.COM Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims page 4 19-23649 Debtor Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 23 of 24 Purdue Pharma L.P. Main Document Pg Case number (if known) Name Name of creditor and complete mailing address, including zip code Name, telephone number, and email address of creditor contact Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts) Indicate if claim is contingent, unliquidated, or disputed Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim. Total claim, if partially secured 40 PC WORKFORCE SOLUTIONS LlC CHERISH CHONG PO BOX 534305 TLANTA, GA 30353 Unsecured claim TRADE DEBT $148,537 EZENHALLRESOURCES TiN: MAYA SHACKLEY PHONE:202-534-3170 EMAIL: MSHACKLEY@DEZENHALL.COM TRADE DEBT $142,835 SHIAND SPECIALTY INGREDIENTS GP TTN: BR KINSEY HONE: 302-594-5000 MAIL: BRKINSEY@ASHLAND.COM TRADE DEBT $140,487 CIECURE PHARMA INC TTN: PURL HONE: 908-723-1209 EMAIL: NOLAN.WANG@SCIECUREPHARMA.COM TRADE DEBT $139,364 RONTAGE LABORATORIES INC TTN: KEVIN LI DONGMEI WANG,SVP/G M,CMC ERVICES HONE:484-362-0395 MAIL: KLI@FRONTAGELAB.COM TRADE DEBT $122,902 OBBS CREEK HEALTHCARE LLC ~N:JUN HUANGPU HONE: 610-513-8740 MAIL: HUANG PU@COBBSCREEKHEALTHCARE.COM TRADE DEBT $116,256 BIOECLIPSE LLC PO BOX 512323 PHILADELPHIA, PA 19175 IOECLIPSE LLC MAIL: MWEBSTER@THEACCESSGP.COM TRADE DEBT $113,381 LATTAIRTECHNIQUESINC TEPHEN RADOVANOVICH 20 SPEAR RD RAMSEY, NJ 07446-1221 LATE AIR TECHNIQUESINC TTN: STEPHEN RADOVANOVICH HONE: 201-825-6337 MAIL: STEPHEN.RADOVANOVICH@GLATT.COM TRADE DEBT $109,135 ACKAGING COORDINATORS INC TTN:JIM HANEY HONE:815-484-8900 MAIL:IIM.HANEY@PCISERVICES.COM TRADE DEBT $108,815 LTERGON ITALIA SRL I NCENZO MANNA ONA INDUSTRIALE ASI MORRA DE SANCTIS, AV 83040 ITALY LTERGON ITALIA SRL TTN: VINCENZO MANNA MAIL: V.MANNA@ALTERGON.IT TRADE DEBT $107,512 HATCHER COMPANY PATRICK SCHWARTZ 1905 FORTUNE RD ALT LAKE CITY, UT 84127 HATCHER COMPANY TTN: PATRICK SCHWARTZ HONE:801-972-4606 MAIL: PATIRCK.SCHWARTZ@TCHEM.COM TRADE DEBT $103,393 ~ DEZENHALLRESOURCES MAYA SHACKLEY 1130 CONNECTICUT AVENUE NW ASHINGTON, DC 20036-3904 42 PC WORKFORCE SOLUTIONS LLC ~N:CHERISH CHONG HONE: 305.490.6535 MAIL: CCHONG@WORKFORCELOGIQ.COM Deduction for value of collateral or setoff SHLAND SPECIALTY INGREDIENTS GP BR KINSEY 8145 BLAZER DR WILMINGTON, DE 19808 43 CIECURE PHARMA INC PURL 11 DEER PARK DR STE 120 MONMOUTH JUNCTION, NJ 08852 44 FRONTAGE LABORATORIES INC KEVIN LI DONGMEI WANG,SVP/G M,CMC SERVICES 700 PENNSYLVANIA DR EXTON, PA 19341-1129 5 C0885 CREEK HEALTHCARE LLC U N HUANGPU 200 MORGAN AVE HAVERTOWN, PA 19083 46 ~ 4$ PACKAGING COORDINATORS INC I M HANEY 545 ASSEMBLY DR ROCKFORD, 1161109 9 5O Official Form 204 Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 50 Largest Unsecured Claims page 5 19-23649 Debtor name Doc 1 Filed 09/15/19 Entered 09/15/19 23:22:53 24 of 24 Main Document Pg Purdue Pharma L.P. United States Bankruptcy Court for the SOUTHERN DISTRICT OF NEW YORK Case number (if known) ❑ Check if this is an amended filing Official Form 202 Declaration Under Penalty of Perjury for Non-Individual Debtors 12/15 An individual who is authorized to act on behalf of anon-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011. WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to $500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571. Declaration and signature am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case. have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct: ❑ ❑ ❑ ❑ ❑ ❑ ❑ ~ Schedule A/8: Assets—Real and Personal Property (Official Form 206A/B) Schedule D: Creditors Who Have Claims Secured by Property (Official Form 206D) Schedule E/F: Creditors Who Have Unsecured C/aims (Official Form 206E/F) Schedule G: Executory Contracts and Unexpired Leases (Official Form 206G) Schedule H: Codebtors (Official Form 206H) Summary of Assets and Liabilities for Non-Individuals (Official Form 206Sum) Amended Schedule Chapter 71 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders (Official Form 204) ~ Other document that requires a declaration Corporate Ownership Statement declare under penalty of perjury that the foregoing is true and correct. Executed on September 15, 2019 X ~~ / `~ Signature of individual signing on behalf of debtor Jon Lowne Printed name A uthorized Person Position or relationship to debtor Official Form 202 Declaration Under Penalty of Perjury for Non-Individual Debtors